Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

JAZZ PHARMACEUTICALS

Filed by TIBER CREEK GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 18, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
8413aed0-9e07-41fc-98c8-6a31c5e6b89b
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxifying hemp.

MED · Medical/Disease Research/Clinical Labs

Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.

BUD · Budget/Appropriations

Appropriations issues related to House Ag/FDA Appropriations pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products; Ag/ FDA amendment - technical correction to the 2026 Ag/ FDA appropriations bill related to hemp; Issues related to intoxifying hemp products.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.